Evaluation of the efficacy and safety of Vismed® Gel Multi 0.3% versus Vismed® Multi 0.18%
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Hyaluronic acid (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors Horus Pharma
- 11 Dec 2018 Planned End Date changed from 31 Dec 2018 to 28 Feb 2019.
- 29 Jun 2018 New trial record
- 22 Jun 2018 Status changed from not yet recruiting to recruiting.